dr. wakelee on recent advancements in egfr-mutant nsclc
Published 6 years ago • 279 plays • Length 1:05Download video MP4
Download video MP3
Similar videos
-
1:57
dr. wakelee on benefits of osimertinib in egfr-mutant nsclc treatment
-
1:16
dr. wakelee on first-line therapy for egfr-mutant lung cancer
-
2:03
dr. wakelee on rationale to explore osimertinib with concurrent chemotherapy in egfr-mutant nsclc
-
1:27
dr. wakelee discusses egfr tkis in lung cancer
-
2:19
dr. wakelee on detection of egfr t790m mutation in nsclc
-
1:29
dr. wakelee on available treatments following tumor progression in lung cancer
-
1:36
dr. heather wakelee on what to do when resistance to egfr tkis emerges
-
1:23
dr. wakelee discusses current state of treatment in nsclc
-
1:03
dr. wakelee discusses dacomitinib in egfr nsclc
-
1:57
dr. piotrowska on treatment for egfr-mutant nsclc
-
2:18
dr. wakelee on first trial to combine antiangiogenesis agents with immunotherapy in nsclc
-
31:53
perspectives on egfr-mutant and wildtype nsclc: tailoring treatment advances in late-stage disease
-
1:37
dr. konduri on treatment options for patients with egfr-mutant nsclc
-
1:37
dr. yu on treatments for egfr-mutant lung cancer
-
8:11
advances in frontline therapy for egfr nsclc
-
1:21
dr. wakelee on importance of ngs testing in nsclc
-
6:56
first-line therapy in the patient with egfr-mutant lung cancer
-
3:55
egfr-mutant nsclc: optimizing therapy selection
-
1:25
current treatment recommendations and future directions for egfr-mutant nsclc